Home › Funds › Lion Point Capital, LP › CUE

Lion Point Capital, LP position in CUE

CUE BIOPHARMA · Health Care

Lion Point Capital, LP reported holding 52,928 shares of CUE (CUE BIOPHARMA) in its Q2 2026 13F filing — a position valued at US$1.7M, representing 7.99% of its reported portfolio and ranking #1 among its reported holdings. Lion Point Capital, LP has disclosed CUE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)52.93K sh
Reported value held$1.67M
Portfolio Weight7.99%
First reportedQ4 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lion Point Capital, LP's CUE position evolved

Lion Point Capital, LP first disclosed a stake in CUE in Q4 2025 at 2,202,854 shares (US$673K). The position peaked in Q2 2026 at 52,928 shares, worth US$1.7M. Across 3 filings, Lion Point Capital, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 52,928 shares valued at US$1.7M — a reduction of -2,149,926 shares quarter over quarter.. Notable position changes include a 98% trim in Q2 2026 (shares fell 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 2.20M $672.75K New
Q1 2026 2.20M $506.44K Hold
Q2 2026 52.93K $1.67M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CUE and 13F data

CUE (CUE BIOPHARMA) is a Health Care company. 28 other funds we track also report a position in CUE — the largest reported positions include Bleichroeder LP (US$11.7M), Tetragon Partners GP Ltd (US$3.0M), Squadron Capital Management LLC (US$1.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CUE

All CUE fund holders →

FAQ

How long has Lion Point Capital, LP held CUE?

Lion Point Capital, LP has disclosed CUE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Lion Point Capital, LP's current position in CUE?

As of Q2 2026, Lion Point Capital, LP holds 52.93K shares of CUE (CUE BIOPHARMA), valued at $1.67M, representing 7.99% of its reported portfolio and ranking #1.

Has Lion Point Capital, LP been buying or selling CUE?

In the latest 13F filing (Q2 2026), Lion Point Capital, LP reduced its position in CUE. The position peaked in Q2 2026 at 52.93K shares.

Which other funds hold CUE?

Other major institutional holders of CUE include Bleichroeder LP, Tetragon Partners GP Ltd, Squadron Capital Management LLC, among 28 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.